drugset / Trial / NCT03818672
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to characterize the steady state plasma
Timeline
- Start
- 2019-01-29
- Primary completion
- 2020-02-02
- Completion
- 2020-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 550 mg | — |
Indications
No indication recorded.